Anti-Viral Therapeutics Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 56.71 Billion |
| Market Size (2030) | USD 62.80 Billion |
| CAGR (2025 - 2030) | 2.06% |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Anti-Viral Therapeutics Market Analysis
The Anti-Viral Therapeutics Market size is estimated at USD 56.71 billion in 2025, and is expected to reach USD 62.80 billion by 2030, at a CAGR of 2.06% during the forecast period (2025-2030).
The sudden outbreak of COVID-19 had an optimistic effect on the global anti-viral therapeutics market's growth. The strong market growth due to the COVID-19 pandemic was mainly attributed to the increasing focus of major market players on developing COVID-19 drugs. For instance, in January 2022, Pharma major Lupin launched the antiviral drug Molnupiravir in India under the brand name Molnulup for treating COVID-19 adults in the country. Furthermore, Emcure Pharmaceuticals received an Emergency Use Authorisation (EUA) approval from the Drug Controller General of India (DCGI) for launching Molnupiravir to treat mild COVID-19. The company plans to launch the oral drug under the brand Lizuvira in the Indian market. Thus, the market responded to the effect quickly and changed in a way that accelerated market growth.
Similarly, product launches are another factor boosting the growth of the market. For instance, in November 2021, Pfizer Inc. announced its investigational COVID-19 oral antiviral candidate, PAXLOVID, and claimed to significantly reduce hospitalization and mortality rate based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. The anti-viral therapeutics market is expected to witness an upsurge mainly due to the increasing patient population in the world. According to WHO, globally, 38.4 million people were living with HIV at the end of 2021. An estimated 0.7% of adults aged 15-49 years worldwide live with HIV; however, the epidemic's burden continues to vary considerably between countries and regions. Thus, with an increase in HIV cases, the need for its therapy increased, leading to market growth.
Moreover, intense research & development pipelines of the major players and increasing product launches are the key drivers in the growth of the antiviral therapeutics market. For instance, in April 2021, Atriva Therapeutics GmbH received USD 12.05 million (EUR 11.4 million) in federal funding. The company will use the funds to advance its drug ATR-002, which is currently in a Phase II clinical study called RESPIRE. Anti-viral therapeutics are commercially available for diseases like influenza, hepatitis C, chickenpox, papilloma, and AIDS.
Thus, the abovementioned factors are impacting the market growth for the anti-viral therapeutics market. However, the high cost of anti-viral drug treatment is expected to restrain the market growth.
Anti-Viral Therapeutics Market Trends
Influenza Anti-viral Drugs Segment Expected to Hold Significant Market Share over the Forecast Period
Influenza is an infection of a part of the respiratory system, i.e., the nose, throat, and lungs. The primary reason for the growth of the influenza anti-viral drugs segment is the global prevalence of influenza and the increasing number of drug launches. According to the data published by the Centers for Disease Control and Prevention, in February 2022, the common cold causes 22 million school days to be missed each year in the United States. Also, in the United States, almost 1 billion people have colds each year. Furthermore, according to the estimates published by the Centers for Disease Control and Prevention (CDC), 1,675 (0.2%) of 818,939 respiratory specimens tested by United States clinical laboratories were found positive for an influenza virus from September 28, 2020, to May 22, 2021.
To cater to the significant unmet needs in the market, players are focusing on research & development with potential candidates. For instance, in August 2022, Genentech, a member of the Roche Group, announced that the United States FDA had approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute, uncomplicated influenza in otherwise healthy children aged between 5 years to less than 12 years, who have been symptomatic for no more than 48 hours. The novel launch of products from this strong pipeline is anticipated to propel market growth over the forecast period.
Therefore, the factors mentioned above are expected to drive segmental growth in the market during the forecast period.
North America Expected to Continue Market Dominance over the Forecast Period
North America is anticipated to continue to dominate the anti-viral therapeutics market over the forecast period due to the presence of well-established market players along with the growing prevalence of HIV and other viral infections. For instance, according to an article published by HIV.gov, in October 2022, approximately 1.2 million people in the United States had HIV. About 13% are unaware of the disease and need HIV testing. Furthermore, the market's growth in the North American region is also attributed to the increasing investments in research & development by major players and robust drug approvals by the US Food and Drug Administration (FDA) in recent years. For instance, in December 2021, the FDA considered authorizations for Pfizer's PAXLOVID and Merck & Co.'s MOLNUPIRAVIR, the first two oral COVID-19 antivirals.
Similarly, product approval is another factor driving the growth of the market. For instance, in December 2021, Pfizer Inc. announced that the United States FDA had authorized the emergency use of PAXLOVID to treat mild-to-moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing and who are at high-risk for progression to severe COVID-19.
Thus, owing to the abovementioned factors, the North American region is expected to drive market growth during the forecast period.
Anti-Viral Therapeutics Industry Overview
The anti-viral therapeutics market is moderately competitive. Some of the major players in the anti-viral therapeutics market are AbbVie Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, Merck and Co. Inc. The anti-viral therapeutics market is a fast-growing market. The major players in the market are adopting organic and inorganic strategies to survive and expand. Moreover, the key players are focusing on increasing US Food and Drug Administration (FDA) approvals and product launches to leverage current and future market opportunities.
Anti-Viral Therapeutics Market Leaders
-
AbbVie Inc.
-
Bristol-Myers Squibb Company
-
Gilead Sciences Inc.
-
F. Hoffman-La Roche Ltd
-
Cipla Inc.
- *Disclaimer: Major Players sorted in no particular order
Anti-Viral Therapeutics Market News
- In January 2022, Aurobindo Pharma Limited launched molnupiravir under the brand name Molnaflu for COVID-19 treatment in India. This strengthened the company's product portfolio, thereby creating revenue growth opportunities.
- In January 2022, Lupin launched the anti-viral drug Molnupiravir in India under the brand name Molnulup to treat adults suffering from COVID-19 in the country.
- In January 2022, ENTOD Pharmaceuticals launched MOLENTOD in India. The product was made available at affordable prices at retail chemists, pharmacy chains, hospitals, and online stores.
Anti-Viral Therapeutics Industry Segmentation
Anti-viral drugs are a class of medication used for treating viral infections. While a broad-spectrum antiviral is effective against many viruses, most antivirals target specific viruses.
Anti-viral Therapeutics Market is Segmented by Drug Type (Herpes Anti-viral Drugs, Hepatitis Anti-viral Drugs, HIV Anti-viral Drugs, Influenza Anti-viral Drugs, and Other Anti-viral Drugs), Distribution Channel (Hospital Pharmacy, Independent Pharmacy, and Drug Store, Online Pharmacy), and Geography (North America (United States, Canada, and Mexico), Europe ) Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and the Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers value (in USD billion) for the above segments.
| By Drug Type | Herpes Anti-viral Drugs | ||
| Hepatitis Anti-viral Drugs | |||
| HIV Anti-viral Drugs | |||
| Influenza Anti-viral Drugs | |||
| Other Drug Types | |||
| By Distribution Channel | Hospital Pharmacy | ||
| Independent Pharmacy and Drug Store | |||
| Online Pharmacy | |||
| By Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle-East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle-East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Herpes Anti-viral Drugs |
| Hepatitis Anti-viral Drugs |
| HIV Anti-viral Drugs |
| Influenza Anti-viral Drugs |
| Other Drug Types |
| Hospital Pharmacy |
| Independent Pharmacy and Drug Store |
| Online Pharmacy |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle-East and Africa | GCC |
| South Africa | |
| Rest of Middle-East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Anti-Viral Therapeutics Market Research FAQs
How big is the Anti-Viral Therapeutics Market?
The Anti-Viral Therapeutics Market size is expected to reach USD 56.71 billion in 2025 and grow at a CAGR of 2.06% to reach USD 62.80 billion by 2030.
What is the current Anti-Viral Therapeutics Market size?
In 2025, the Anti-Viral Therapeutics Market size is expected to reach USD 56.71 billion.
Who are the key players in Anti-Viral Therapeutics Market?
AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences Inc., F. Hoffman-La Roche Ltd and Cipla Inc. are the major companies operating in the Anti-Viral Therapeutics Market.
Which is the fastest growing region in Anti-Viral Therapeutics Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Anti-Viral Therapeutics Market?
In 2025, the North America accounts for the largest market share in Anti-Viral Therapeutics Market.
What years does this Anti-Viral Therapeutics Market cover, and what was the market size in 2024?
In 2024, the Anti-Viral Therapeutics Market size was estimated at USD 55.54 billion. The report covers the Anti-Viral Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Anti-Viral Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on: August 8, 2024
Anti-Viral Therapeutics Industry Report
The global antiviral drugs market is experiencing dynamic shifts influenced by various market segments and trends. The persistent prevalence of viral diseases such as HIV, hepatitis, and influenza continues to drive the need for effective treatments. The market is segmented into branded and generic drugs, with branded drugs currently leading due to their established efficacy and safety profiles. However, the generic segment is anticipated to grow rapidly, driven by the demand for more affordable medication options in developing regions. Significant research and development activities are leading to the approval and commercialization of novel antiviral drugs, supported by strategic collaborations among key market players and research institutions. Yet, the high cost of antiviral drugs remains a major barrier, particularly in low- and middle-income countries. For a detailed analysis of the anti-viral drugs market size, share, revenue growth rate, and a forecast outlook, download a free report PDF from Mordor Intelligenceâ„¢ Industry Reports. This comprehensive overview will benefit anti-viral drugs market companies navigating through innovation, regulation, and market competition challenges.
